Krishnamoorthy, J., Rajesh, K., Mirzajani, F., Kesoglidou, P., Papadakis, A. I., & Koromilas, A. E. (2014). Evidence for eIF2α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications. Landes Bioscience.
Citação norma ChicagoKrishnamoorthy, Jothilatha, Kamindla Rajesh, Farzaneh Mirzajani, Polixenia Kesoglidou, Andreas I. Papadakis, and Antonis E. Koromilas. Evidence for EIF2α Phosphorylation-independent Effects of GSK2656157, a Novel Catalytic Inhibitor of PERK With Clinical Implications. Landes Bioscience, 2014.
Citação norma MLAKrishnamoorthy, Jothilatha, et al. Evidence for EIF2α Phosphorylation-independent Effects of GSK2656157, a Novel Catalytic Inhibitor of PERK With Clinical Implications. Landes Bioscience, 2014.